NEW YORK (360Dx) — Svar Life Science, formerly Euro Diagnostica, has signed a strategic agreement to transfer its radioimmunoassay (RIA) portfolio and its Neolisa chromogranin A (CgA) ELISA assay to Diasource ImmunoAssays, the companies announced today.

Under the terms of the deal, Diasource will assume sales of the RIA products beginning Sept. 1 and take over the products' production during the remainder of the year. Diasource will begin selling the Neolisa CgA assay in January 2019, with production transfer following later that year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.